Linkedin
RLS logo_header
Search
Close this search box.
Linkedin
Search
Close this search box.

Submission of New Drug Application for Glecirasib announced

Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: “Since its establishment in 2015, Jacobio has been committed to develop the undruggable targets. Glecirasib’s NDA  submission is a milestone for the company and also marks that Jacobio will enter the commercialization stage. NDA submission is just the beginning. We will continue to explore the potential of glecirasib as a single agent and combination therapy in the fields of lung cancer, pancreatic cancer, colorectal cancer and multi-tumors basket to solve the actual clinical needs of more patients.

Read the full story on "Submission of New Drug Application for Glecirasib announced"

Share:

More News

Phanes Therapeutics Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy

“Phanes is very excited about partnering with Roche on this novel approach to treat patients with SCLC, LCNEC and EP-NECs,” said Rita Laeufle, MD, PhD, Chief Medical Officer (CMO) of Phanes. “DLL3 is highly expressed in SCLC, LCNEC and EP-NECs and an important target for treating these cancers. We believe

Phase 3 KeyVibe-010 Trial of Vibostolimab and Pembrolizumab coformulation as Adjuvant Treatment for Patients With Resected High-Risk Melanoma unlikely to achieve a statistically significant improvement in RFS

“Through our clinical development program, we continue to ask the tough questions in an effort to fully explore the potential of novel coformulations and combinations that build on the foundation of KEYTRUDA, with a goal to improve upon current standards of care and help even more patients with cancer,” said

VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

“The VERSATILE-002 trial is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive HNSCC. Median overall survival (“mOS”) is 30 months (n=53) in first line recurrent metastatic HNSCC; Published results for immune checkpoint inhibitors are 7-18 months. The immune checkpoint inhibitor (ICI) naïve cohort (n=53) met its primary endpoint

FDA Grants Orphan Drug Designation to 9MW2821

“Mabwell (688062.SH) announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer. 9MW2821 was previously given Fast Track Designation (FTD) by the FDA for the treatment of advanced, recurrent,

Onco-This-Week

About Us

Sign up for OTW

Linkedin
Search
Close this search box.

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.